The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
OTEZLA offers convenient, oral dosing1
Treatment begins with a 5-day titration1:
After the titration period, the maintenance dose of OTEZLA is 30 mg twice daily for most patients1
The dose of OTEZLA should be reduced to 30 mg once daily in patients with severe renal impairment1*:
*Creatinine clearance (CrCl) <30 mL/min estimated by the Cockcroft-Gault equation.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.